Proscia and Datavant Partner to Connect Pathology Data Ecosystem for Life Sciences R&D
Data accessibility and interoperability will accelerate translational medicine and development of therapeutic breakthroughs
January 13, 2022, Philadelphia, PA and San Francisco, CA – Proscia, the leader in digital and computational pathology solutions, and Datavant, the leader in helping organizations securely connect health data, today announced a partnership that will provide life sciences companies with digitized pathology data to power the development of novel therapeutics and diagnostics. The partnership brings together Datavant's patient privacy-preserving connectivity technology and the largest U.S. health data ecosystem with Proscia's Concentriq® digital pathology platform.
Pathology is undergoing a transformation to an image-based, data-driven paradigm across life sciences and diagnostics as labs shift from 150-year-old analog microscope-based practices. According to the CDC, 70% of medical decisions are based on laboratory data, much of which has remained siloed and disconnected from the flourishing healthcare data landscape. Pathology's digital transformation, which has been accelerated by the COVID-19 pandemic and technology tailwinds, represents the emergence of one of the largest and richest new data mediums in healthcare. Proscia's proprietary platform technology is powering diagnostic labs and life sciences organizations today, including 10 of the top 20 biopharma companies.
Datavant's technology, combined with Proscia's platform and extensive library of pathology data, will help life sciences organizations link digital images, curated cancer datasets, and structured insights with other healthcare data in a privacy-preserving way to power next-generation R&D. This compliant linkage will support the development of novel biomarkers, accelerate clinical trials, and enable real-world evidence in pharma.
“We've seen a wellspring of demand for structured pathology data, married with computational technologies, to power precision medicine R&D,” said David West, CEO of Proscia. “Our partnership with Datavant does two things: first, it brings new tools for protecting patient privacy, data security, and HIPAA compliance to our Concentriq base. Second, it helps link pathology data with partners in the Datavant ecosystem. Together, this will enable pharma and biotech companies to leverage this new digital medium, cultivating the advancement of new therapies and diagnostics. Ultimately, this data partnership represents the third prong of Proscia's mission to accelerate medical breakthroughs with our platform, AI and data.”
“Pathology data is one of the most difficult sources of data to transform into usable information,” noted President and Co-Founder of Datavant, Travis May. “Enabling compliant connectivity of digital pathology data to other research data bridges bench science and outcomes research, scaling and accelerating the development of highly tailored precision therapeutics for patients.”
Proscia is a software company that is changing the way the world practices pathology to transform research and diagnosis for diseases like cancer. With the company's Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia's team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision diagnostics. For more information, visit proscia.com.
Datavant's mission is to connect the world's health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building neutral, trusted and ubiquitous technology that protects the privacy of patients while supporting the exchange of identified and de-identified health data across tens of thousands of healthcare institutions.